Aurora Kinases: New Molecular Targets for the Therapy of Aggressive Thyroid Cancers by Baldini, Enke et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 4
Aurora Kinases: New Molecular Targets for the
Therapy of Aggressive Thyroid Cancers
Enke Baldini, Chiara Tuccilli, Salvatore Sorrenti,
Domenico Mascagni, Stefano Arcieri,
Angelo Filippini and Salvatore Ulisse
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/64597
Provisional chapter
Aurora Kinases: New Molecular Targets for the Therapy
of Aggressive Thyroid Cancers
Enke Baldini, Chiara Tuccilli, Salvatore Sorrenti,
Domenico Mascagni, Stefano Arcieri,
Angelo Filippini and Salvatore Ulisse
Additional information is available at the end of the chapter
Abstract
Epithelial  thyroid  carcinomas  (TC)  account  for  more  than  90%  of  all  endocrine
malignancies and represent one of the most frequent cancers in women. They include
the well-differentiated TC (DTC), comprising the papillary (PTC) and follicular (FTC)
histotypes, the poorly differentiated (PDTC), and the undifferentiated or anaplastic TC
(ATC). Both PDTC and ATC are aggressive human neoplasms with a dire prognosis due
to the absence of effective therapies, which makes mandatory the identification of novel
therapeutic strategies. Intrinsic chromosomal instability (CIN, an increased rate of gain
or losses of chromosomes during cell division) is a common feature of solid tumors and
represents a major driving force in thyroid cancer progression, thought to be responsible
for the acquisition by malignant cells of novel functional capabilities. Different mitotic
kinases, whose expression or function has been found altered in human cancer tissues,
are major drivers of thyroid tumor aneuploidy. Among these are the three members of
the Aurora family (Aurora-A, Aurora-B and Aurora-C), serine/threonine kinases that
regulate multiple aspects of chromosome segregation and cytokinesis. Over the last few
years, several small molecule inhibitors targeting Aurora kinases were developed with
promising antitumor effects in preclinical and clinical studies against different human
cancers, including TC. Here, we will focus on the Aurora mitotic functions in normal
cells; we shall then describe the main implications of their overexpression in the onset
of genetic instability and aneuploidy.  We will  finally describe the consequences of
Aurora kinase inhibition on TC cell growth and tumorigenicity.
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1. Introduction
The incidence of thyroid cancer (TC) has increased from about five new cases per 100,000
persons observed in the early 90s to 15 new cases per 100,000 persons recorded in 2012 [1].
This increase is mainly due to the improved ability to detect malignancy in small thyroid
nodules [2, 3]. TC represents about 96% of all endocrine malignancies and one of the most
frequent cancers in women [1]. Based on histological and clinical criteria, TC are classified as
well-differentiated  TC  (DTC),  which  includes  the  papillary  (PTC)  and  follicular  (FTC)
histotypes, poorly differentiated TC (PDTC), and anaplastic TC (ATC). The PTC accounts for
about 86% of all epithelial TC. It appears as a mass of branching papillae covered by cells with
eosinophilic cytoplasm and enlarged nuclei and typically metastasizes via lymphatic vessels
to local lymph nodes [4]. The FTC accounts for approximately 9% of all TC. It resembles the
normal microscopic pattern of the thyroid and is characterized by hematogenous spread
producing lung and bone metastases [4]. The less differentiated and more aggressive PDTC
and ATC,  each of  which accounts  for  1–2% of  all  TC,  are  thought  to  develop from the
dedifferentiation of DTC, according to the multistep model of thyroid carcinogenesis [4–8].
The PDTC was included as a separate entity in the WHO classification of TC in 2004. PDTC
retains sufficient differentiation to produce scattered small follicular structures and some
thyroglobulin but generally lacks the usual morphologic characteristics of DTC, showing an
intermediate clinical behavior between DTC and ATC. In addition, it is characterized by high-
grade features such as widely infiltrative growth, necrosis, vascular invasion, and numerous
mitotic figures [6, 9].  The ATC is composed of disseminated fleshy masses with areas of
necrosis  and  hemorrhage.  The  cells  have  an  undifferentiated  phenotype  with  marked
cytological atypia and high mitotic activity, and they are negative for thyroglobulin [4].
Established risk factors for TC include radiation exposure, family history of TC, lymphocytic
thyroiditis, reduced iodine intake, and female gender [10]. All of them are thought to induce
chromosome instability (CIN) in thyrocytes through still poorly defined direct and indirect
mechanisms [10–13]. Actually, number and frequency of chromosomal abnormalities increase
from DTC to PDTC and ATC [13]. CIN is also sustained by alterations in cell cycle regulators,
frequently encountered in TC [10]. In particular, a deregulated control of the G1/S transition,
following either an increased expression of promoting factors (cyclin D1 and E2F) or the
downregulation or presence of loss-of-function mutations of factors inhibiting the G1/S
transition (retinoblastoma, p16INK4A, p21CIP1, p27KIP1, and p53), has been documented in
TC [10]. In addition, the aberrant expression of mitotic kinases, such as the polo-like kinase
and the three members of the Aurora kinase family, is held co-responsible for abnormal cell
divisions and the establishment of aneuploid TC cells [14, 15].
About 80% of PTC are characterized by mutually exclusive activating somatic mutations of
genes encoding for proteins involved in the mitogen-activated protein kinase (MAPK)
signaling pathway [4, 16]. These include rearrangements of the RET (rearranged during
transformation) (RET/PTC) and neurotrophic tyrosine kinase receptor 1 (NTRK1) genes, and
activating point mutations of the three RAS oncogenes (HRAS, KRAS, and NRAS) and BRAF
[16]. In addition, mutations of genes encoding key players of the phosphoinositide 3-kinase
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(PI3K) pathway, such as PTEN, PIK3CA, and AKT1, have been reported in PTC at lower
frequencies [16]. Genetic alterations encountered in FTC include activating point mutations of
RAS, present in about 45% of FTC; rearrangement of the paired-box gene 8 (PAX-8) with the
peroxisome proliferator-activator receptor-γ (PAX8-PPARγ), observed in 35% of FTC; loss-of-
function mutations of the tumor suppressor PTEN gene, encountered in about 10% of FTC;
activating mutations or amplification of the PI3KCA gene, present in about 10% of FTC [17, 18].
Progression of DTC to PDTC and ATC implies tumor acquisition of novel genetic alterations,
which are absent or present with low frequency in DTC tissues. Among these are mutations
of the tumor suppressor gene p53, thought to be a gatekeeper of TC progression from the
indolent DTC to the aggressive PDTC and lethal ATC [19]. In fact, p53 mutations are rarely
encountered in DTC (5–9% of cases), while increase in the PDTC (17–38% of cases) and ATC
(67–88% of cases) [10, 20, 21]. A similar trend regards the CTNNB1 gene, encoding the β-
catenin, involved in cell adhesion and in the wingless (Wnt) signaling pathway [10]. In
particular, CTNNB1 gene mutations are not found in DTC, while they are present in PDTC
(25% of cases) and ATC (66% of cases) [22, 23]. The conversion of early-stage TC to more
aggressive and invasive malignancies occurs through an epithelial-to-mesenchymal transition
(EMT), which implies the loss of cell-cell contacts, remodeling of cytoskeleton, and the
acquisition of a migratory phenotype [24, 25]. Reduced expression of E-cadherin and abnormal
expression of integrins, Notch, MET, TGFβ, NF-kB, PI3K, TWIST1, matrix metalloproteinases,
components of the urokinase plasminogen-activating system and p21-activated kinase, all of
them involved in the EMT, have been identified in TC progression [24–29].
Total thyroidectomy followed by adjuvant therapy with radioactive iodide (131I) is the treat-
ment of choice for the majority of patients affected by DTC [30]. Although the prognosis of
these patients is favorable, with 10-year survival rate around 90%, about one-third of them face
the morbidity of disease recurrence and TC-related deaths [30]. The worst outcomes are
observed in patients with PDTC and ATC, in which the reduced expression of the thyroid-
specific gene natrium/iodide symporter (NIS) renders 131I treatment useless [31–33]. In
particular, patients affected by ATC have a dismal prognosis with a mean survival time of few
months from the diagnosis [32]. Outcome of ATC patients is not influenced by current
anticancer treatments (i.e., palliative surgery when possible, chemotherapy, and radiotherapy),
and in the majority of cases, death occurs following tumor airway obstruction [34]. Thus, the
identification of novel therapeutic approaches capable of improving PDTC and ATC patients’
outcome is very much needed.
2. The Aurora kinases
The Aurora kinases belong to a family of serine/threonine kinases having in the Ipl1p (Increase
in ploidy 1) gene, subsequently named Aurora gene, the founding member discovered in the
budding yeast Saccharomyces cerevisiae during a genetic screening for mutations causing
defective chromosomal segregation [35–38]. In mammals, the Aurora kinase family includes
three proteins: Aurora-A, Aurora-B, and Aurora-C [39]. Structurally, they are characterized by
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three domains: a N-terminal domain with little similarity among the three Aurora kinases,
instrumental in determining their different intracellular localizations, substrate specificity and
functions; a catalytic domain, containing the activation loop and highly related in sequence
among the three proteins; and a short C-terminal domain of 15–20 residues (Figure 1). Aurora
kinase expression is tightly regulated during cell cycle, being low in the G1/S phase and
maximal in the G2/M phase.
Figure 1. Schematic representation of Aurora kinase proteins. D-Box, destruction box; DAD, D box activating domain;
KEN motif, amino acidic K-E-N, which serves as targeting signal for the Cdh1–anaphase promoting complex (adapted
with permission from Ref. [14]).
2.1. Aurora-A
The Aurora-A is encoded by the AURKA gene located on the chromosome 20q13.2 and
containing 11 exons (Gene ID: 6790). The AURKA promoter contains a putative TATA box at
−37 to −14 and two CCAAT boxes at −101 to −88 and at −69 to −56 [Eukaryotic Promoter
Database, Swiss Institute of Bioinformatics]. Two distinct cis-regulatory elements have been
identified [40]. Of these, one positively regulates AURKA gene transcription, while the other
is a cell cycle-dependent transcriptional repressor [40]. The former, essential for the gene
expression, is a 7-bp sequence located at −85 to −79 that binds the transcription factor E4TF1.
The second is formed by two repressor elements: a cell cycle-dependent element (CDE) located
at −44 to −40, and a cell cycle gene homology region (CHR) located at −39 to −35 [40]. Over the
last few years, a number of transcription factors capable of repressing or inducing AURKA
gene expression have been identified. These include the p53, the HIF-1, and the INI1/hSSNF5,
all reported to regulate negatively the activity of the AURKA promoter [41–43]. Conversely,
other transcription factors have been shown to induce AURKA expression, among which the
ΔEGFR/STAT5, the oncogene MYCN, and the MAPK via Ets2 transcription factors [44–47]. The
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Aurora-A protein consists of 403 amino acids with a predicted molecular mass of 45.8 kDa
(Figure 1). In the activation loop, an Aurora kinase signature (xRxTxCGTx) is present in which
the autophosphorylation of the Thr288 is required for kinase activation [48]. In addition, the
Thr288 is positioned within a protein kinase A (PKA) consensus sequence, and in vitro
experiments indicated a potential role of PKA in Aurora-A phosphorylation [49, 50]. The
phosphatase PP1 has been shown to dephosphorylate and inactivate Aurora-A [16]. The C-
terminal located destruction box (D box), containing the motif RxxLxxG, and the N-terminal
A-box/D-box-activating domain (DAD), containing the motif RxLxPS, play an essential role in
Aurora-A degradation by the anaphase promoting complex/cyclosome (APC/C)-ubiquitin-
proteasome pathway. Aurora-A degradation occurs in late mitosis/early G1 phase, when the
D box is targeted by Fizzy-related proteins that transiently interact with the APC, and it is
dependent from the APC/C activator protein Cdh1 [49–52]. In the N-terminal region the amino
acidic sequence K-E-N, known as KEN motif, is also present, which serves as targeting signal
for Cdh1-APC-mediated degradation of several mitotic proteins such as Nek2 and B99 [53].
However, this does not seem to be crucial for Aurora-A degradation [53]. Phosphorylation of
the serine residue (Ser51) in the DAD domain has been shown to prevent Aurora-A degrada-
tion [54, 55].
2.2. Aurora-B
The Aurora-B is encoded by the AURKB gene mapped to chromosome 17p13.1, and consisting
of nine exons (Gene ID: 9212). Its promoter contains three putative CAAT boxes at −99 to −86,
at −66 to −53, and at −30 to −17 [Eukaryotic Promoter Database, Swiss Institute of Bioinformat-
ics]. As above described for the AURKA promoter, also the AURKB promoter possesses the
CDE and CHR elements, thought to be responsible for the regulation of gene expression
throughout the cell cycle [54]. AURKB promoter activity is positively increased by transcription
factors such the ETS2 via ETS-binding sites present in its sequence [46, 47]. The 1.4 kb transcript
encodes a protein of 345 amino acids with a predicted molecular mass of 39 kDa (Figure 1) [39].
As Aurora-A, Aurora-B protein is characterized by a catalytic domain, a C-terminal D box, and
an N-terminal A box/DAD [49–53]. However, different from Aurora-A, Aurora-B is not
degraded by the same ubiquitin ligase, but following its binding to the human proteasome
α-subunit C8 in a proteasome-dependent manner [55].
2.3. Aurora-C
The Aurora-C is encoded by the AURKC gene localized at chromosome 19q13.43 and consisting
of seven exons (Gene ID: 6795). The AURKC promoter is much less characterized with respect
to those of Aurora-A and Aurora-B. A CCAAT box is present at −36 to −23 (Eukaryotic Promoter
Database, Swiss Institute of Bioinformatics). AURKC promoter activity has been shown to be
downregulated by the transcription factor PLZF [56]. The 1.3 kb transcript encodes a protein
of 309 amino acids with a predicted molecular mass of 35.6 kDa (Figure 1) [39]. Different from
Aurora-A and Aurora-B, Aurora-C does not contain the KEN and the A box/DAD motifs in
its N-terminal region, while the C-terminal D box is present. The mechanism(s) underlying its
degradation, however, still remains to be elucidated.
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3. Expression, subcellular localization, and functions of the Aurora kinases
The Aurora kinases play a major role during mitosis [49, 50]. As mentioned above, these
proteins display distinct intracellular localizations, substrate specificity and functions, and
their expression and activity are tightly regulated at the transcriptional or posttranscriptional
level, through phosphorylation/dephosphorylation and protein degradation [57].
3.1. Aurora-A
The expression of Aurora-A is cell cycle regulated, being very low during the G1-phase and
starting to accumulate at the centrosome in the late S phase to be maximal at the G2-M
transition. In this period, it localizes at the spindle poles, and it is degraded before cytokinesis
[50, 53]. Aurora-A regulates centrosome separation and maturation, mitotic entry, and bipolar
spindle formation. Recruitment of Aurora-A to the centrosome is controlled by the centrosome
Figure 2. (A) Schematic representation of the pathway induced by Aurora-A to activate the CDK1/cyclin B complex
allowing the transition of the cell from the G2 to the M phase. Aurora-A in association with Bora phosphorylates the
PLK1. Both Aurora-A and PLK1 phosphorylate CDC25B (cell division cycle 25 B) allowing cyclin-dependent kinase 1
(CDK1)/cyclin B complex activation and thus promoting mitotic entry. PLK1 facilitates this process also by inhibiting
the CDK1 inhibitor WEE1. Inactivation of Aurora-A or Plk1 individually shows no significant effect on Cdk1 activation
and entry to mitosis, while their simultaneous inactivation produces a marked delay in both Cdk1 activation and mi-
totic entry, suggesting that the two kinases have redundant functions. (B) Immunofluorescence showing Aurora-A lo-
calization at the spindle pole of an anaplastic thyroid cancer cell in metaphase. Adapted with permission from Ref.
[14].
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protein of 192 kDa/spindle defective 2 (Cep192/Spd-2) [58]. On the centrosome, Aurora-A
promotes the concentration in the pericentriolar mass of a number of proteins required for
centrosome maturation and function. These include centrosomin, γ-tubulin, large tumor
suppressor, homolog 2 (LATS2), transforming acidic coiled coil 3 (TACC3), and nuclear
distribution element-like 1 (NDEL1) [50, 53, 59]. A central role of Aurora-A during mitosis is
that to support the microtubule-organizer center (MTOC) responsible for the formation of the
bipolar spindle. In this context, Aurora-A has been shown to form complexes with TACC1 and
TACC3, which in turn, by binding to ch-TOG/XMAP215 proteins, stabilize microtubules at the
centrosome [60–62]. In addition, Aurora-A interacts with and phosphorylates TPX2, which is
capable of promoting spindle microtubule polymerization [53].
Aurora-A, along with the polo like kinase 1 (PLK1), controls the G2 to M phase transition
(Figure 2) [63–65]. First, Aurora-A in association with the Bora protein phosphorylates the
PLK1, after which both Aurora-A and PLK1 phosphorylate the cell division cycle 25 B
(CDC25B), a member of the CDC25 family of phosphatases, which activates cyclin-dependent
kinases by removing two phosphate groups, leading to CDK1/cyclin B complex activation and
finally promoting mitotic entry [50, 63–66]. PLK1 facilitates this process also by inactivating
the CDK1 inhibitor WEE1 (Figure 2).
3.2. Aurora-B
Aurora-B protein level peaks at G2/M phase, with the highest kinase activity recorded from
metaphase to the end of mitosis [49, 50]. Aurora-B acts in concert with three other proteins,
inner centromere protein (INCENP), Survivin, and Borealin/Dasra B, to which it associates
forming the chromosomal passenger complex (CPC). In early prophase, the CPC is located on
chromosomal condensing arms where it displaces the heterochromatin protein-1 from DNA
Figure 3. Schematic representation (A) and immunofluorescence images (B) of Aurora-B localization during mitosis in
an anaplastic thyroid cancer cell. In (B) Aurora-B is in green, microtubules in red and DNA, stained by DAPI, in blue.
Adapted with permission from Ref. [14].
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to recruit condensin proteins (Figure 3) [67, 68]. From early G2 phase to prophase, Aurora-B
phosphorylates histone H3, but its physiological meaning remains unclear. From late prophase
to metaphase CPC localizes to the inner centromere, playing a role in formation and stability
of the bipolar mitotic spindle, kinetochore assembly, correction of non-bipolar chromosome-
spindle attachments, and control of the spindle checkpoint (Figure 3). In anaphase, the CPC
relocates to the midzone of the mitotic spindle and to the cell cortex, remaining evident in the
midbody of telophasic cells where it modulates the activity of several proteins involved in
spindle dynamics, cleavage furrow formation and completion of cytokinesis (Figure 3) [49, 50,
67–69].
Aurora-B activation requires the auto-phosphorylation and binding to INCENP, while all CPC
components are necessary for its proper localization during mitosis. Several kinases, such as
BubR1 and Bub1 (checkpoint kinases), monopolar spindle 1 (Mps1), checkpoint kinase 1
(Chkl), Tousled-like kinase-1, Plk1, and TD-60/RCC2 (regulator of chromosome condensation
2), have been shown to be involved in Aurora-B activation. The phosphorylation status and
activity of Aurora-B are controlled by PP1 and PP2A phosphatases [69].
3.3. Aurora-C
The expression of Aurora-C is maximal during the G2/M phase. This kinase seems to have a
prominent role in the meiotic division, as it is expressed at relative high levels in germ cells
during spermatogenesis and oogenesis, and at very low levels in somatic cells. Aurora-C is
highly similar to Aurora-B in sequence (61% identity), which may explain why the two kinases
display similar localization patterns and share interacting proteins and substrates such as
INCENP, Survivin, Borealin, and others [49, 70]. Interestingly, when ectopically expressed in
cells depleted of Aurora-B, Aurora-C is capable of rescuing the Aurora-B-dependent mitotic
functions [40]. It is also worth to note that Aurora-C has been shown to interact with and
phosphorylate TACC1 in thyroid cells in the cytokinetic bridge [71, 72].
4. Aurora kinases and cancer
Chromosomal instability is thought to represent the mean by which premalignant cells acquire
novel functional capabilities responsible for cancer cell growth and tumor progression [73]. In
fact, aberrations in chromosome number and structure, likely resulting from a combination of
ineffective checkpoints and anomalous cellular divisions, occur in the majority of human
cancers [74]. Given the crucial tasks of Aurora kinases in all mitotic stages, their dysfunction
and/or dysregulation is believed to greatly contribute to aneuploidy. Whether Aurora kinases
may have a role in cancer initiation is still a matter of debate. It has been reported that the
overexpression of either Aurora-A, Aurora-B, or Aurora-C induces cell malignant transfor-
mation [75–77]. In different studies, however, the transforming ability of either Aurora-A or
Aurora-B overexpression could not be confirmed [78, 79].
Aurora-A kinase has been often implicated in cancer progression, and its hyperactivation has
been demonstrated to induce resistance to microtubule-targeted chemotherapy [80–82]. The
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AURKA gene is amplified in many malignancies, and its overexpression has been reported to
be significantly associated with a higher tumor grade and a poor prognosis in a number of
cancers, including chondrosarcoma, nasopharyngeal carcinoma, breast cancer, glioblastoma,
colorectal cancer, gastric cancer, and ovarian carcinoma [83–89]. In addition, somatic mutations
located within the catalytic domain of Aurora-A, altering kinase activity and subcellular
localization, have been described in human cancer cells [90]. The oncogenic potential of
Aurora-A derives from a sum of several spatially and temporally distinct actions. Unlike
normal cells, in many cancer cells the expression of Aurora-A becomes constitutive throughout
the cytoplasm, regardless of the cell cycle phase; this can trigger a plethora of improper
interactions, phosphorylations, and mislocalizations. Aurora-A may also represent the
downstream target of mitogenic pathways, such as MAPK/ERK (mitogen-activated protein
kinases), and be overexpressed because of their constitutive activation in tumors [81]. The
Aurora-A excess interferes with different cell cycle checkpoints, that is, the late G2 checkpoint,
which restrains genetically aberrant cells to enter mitosis, the spindle assembly checkpoint,
which blocks the metaphase–anaphase transition in cells with defective spindles, and the post-
mitotic G1 checkpoint, which arrests cell cycle in aneuploid cells [81, 83]. Centrosome
amplification and unrestrained multinucleation, leading to abnormal mitotic spindle, are also
observed in Aurora-A overexpressing cells [91]. Moreover, Aurora-A may significantly
contribute to tumor progression by interacting with and inhibiting several tumor suppressor
proteins such as p53, BRCA1 (breast cancer 1), and Chfr (checkpoint with forkhead and ring
finger domains). Interestingly, activation of the MAPK signaling pathways has been found to
induce accumulation of Aurora-A kinase in ERα+ breast cancer cells, and epithelial-to-
mesenchymal transition (EMT) [92, 93]. In these cells, Aurora-A has been shown to promote
SMAD5 phosphorylation and nuclear translocation, upregulation of stemness gene SOX-2, and
acquisition of a stem cell-like phenotype [92, 93].
Aurora-B plays a less clear role in tumorigenesis. An increased level of Aurora-B in normal
cells induces premature chromosome separation and segregation errors, promotes generation
of tetraploid/aneuploid cells, and potentiates Ras oncogenic activity [77, 80, 94–96]. Neither
amplification nor specific mutations of AURKB gene have been shown to occur in human
malignancies; nevertheless, Aurora-B overexpression has been demonstrated in several cancer
types, including hepatocellular and oral squamous cell carcinomas, where it correlates with
poor prognosis [80, 94–96].
At present, very little is known about the role of Aurora-C in cancer progression. Although
Aurora-C is almost not detectable in normal somatic cells, it is highly expressed in various
tumor cell lines [97–100]. One study has described the transforming potential of overexpressed
Aurora-C in NIH-3T3 cells, and a correlation between the level of active kinase and tumor
aggressiveness of the cells injected in nude mice [77].
4.1. Aurora kinase inhibitors
The overexpression of Aurora kinases in human cancers and their relevance in controlling
the mitotic process have led to the development of small-molecule inhibitors as anticancer
drugs. Aurora inhibition results in cytokinesis failure and generation of tetraploid cells,
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which, depending on the post-mitotic checkpoint activation, may be unable to proceed in a
new cell cycle or rather may proliferate and become polyploid. The exit from cell cycle is
likely to generate viable quiescent cells, whereas endoreplicating cells have greater tendency
to undergo apoptosis. Actually, the functional inhibition of Aurora kinases is considered a
promising therapeutic option against those malignancies that do not respond to the availa-
ble therapies [101–108]. Up to date, about 30 small-molecule inhibitors of Aurora kinases
have been developed and some of them, reported in Table 1, are being evaluated in Phase I-
II clinical trials [101–108]. Of some interest are the preclinical observations showing the abil-
ity of different Aurora kinase inhibitors to have additive or synergist effects when combined
with other anticancer therapies [109, 110]. At example, among the pan-Aurora kinase inhibi-
tors, the AMG-900 in combination with the HDAC (histone deacetylase) inhibitor vorinostat
has been shown to synergistically reduce proliferation and survival of medulloblastoma and
prostate cancer-derived cell lines [111, 112]. Similarly, the SNS-314 has been shown to pos-
sess additive inhibitory effects on the HCT 116 cell line when combined with either carbo-
platin, gemcitabine, 5-FU, daunomycin, docetaxel, or vincristine [113]. Also the MK-0457
has revealed additive effects when combined with docetaxel on ovarian cancer cell lines or
with cisplatin on the HepG2 cell line [114, 115]. Finally, the pan-Aurora kinase inhibitor
CCT 137690 has been shown to sensitize SW620 colorectal cancer cells to radiotherapy [116].
In clinical trials, disease stabilization and, less frequently, partial responses in patients with
solid cancers have been witnessed with the majority of Aurora kinase inhibitors, while more
encouraging observations have been made in patients with hematological malignancies
[101–110]. On-target toxicity observed with these drugs included grade 3/4 neutropenia, leu-
kopenia, and myelosuppression, while off-target effects included hypertension, somnolence,
mucositis, stomatitis, proctalgia, and ventricular dysfunction [101–110]. For example, the
MK-0457 has been employed in different clinical trials in which patients with advanced sol-
id tumors have been enrolled. In a Phase I dose escalation study, the most common dose-
limiting toxicity observed was neutropenia and herpes zoster, and major adverse events
include nausea, vomiting, diarrhea, and fatigue [117]. Although no objective tumor respons-
es were observed in this trial, 12 of 27 patients experienced stable disease with a median
duration of 75.5 days (range 38–328 days). Of the latter, one patient with ovarian cancer ach-
ieved prolonged stable disease for 11 months, and one patient with rectal cancer had stable
disease over 7 months [117].
The MK-0457 was found to have off-target inhibitory effects on both wild-type and mutant
Abl kinases and showed to be a potent inhibitor of the BCR-ABL T315I mutant, which mediates
clinical resistance to imatinib, nilotinib, and dasatinib [118]. On these bases, a phase I/II dose
escalation study of MK-0457 was performed in patients with leukemias [119, 120]. Patients
with refractory hematologic malignancies received 1–21 cycles of MK-0457, and maximum-
tolerated doses were calculated for a 5-day short infusion as 40 mg. Mucositis and alopecia
were the most common drug-related adverse events observed in these patients. Forty-four
percent (8/18) of patients, positive for the BCR-ABL T315I mutation, affected by chronic
myelogenous leukemia (CML) had hematologic responses, and 33% (1/3) of patients with
Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) obtained
complete remission [119, 120].
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Inhibitor (company) commercial name Clinical trial
Pan-Aurora inhibitors
VX-680/MK-0457 (Vertex/Merck) Tozasertib Phase II (terminated due to severe toxicity)
PHA-739358 (Pfizer/Nerviano) Danusertib Phase II
PHA-680632(Pfizer/Nerviano) Phase II
CYC-116 (Cyclacel) Phase I
SNS-314 (Sunesis) Phase I
R763 (Rigel) Phase I
AMG-900 (Amgen) Phase I
AT-9283 (Astex) Phase II
PF-03814375 (Pfizer) Phase I
GSK1070916 (GlaxoSmithKline) Phase I
Aurora-A inhibitors
MLN8237 (Millennium) Phase II
EMD-2076 (EntreMed) Phase II
MK-5108 (Vertex) Phase I
Aurora-B inhibitors
AZD1152 (AstraZeneca) Phase II
Table 1. Aurora kinase inhibitors in clinical trials (adapted with permission from Ref. [14]).
Another multicenter phase II study evaluated the safety and efficacy of MK-0457 on 52 patients
affected by CML or Ph+ ALL with BCR-ABL T315I mutation [121] (Seymour et al. 2014).
Patients were treated with a 5-day continuous infusion of MK-0457 administered every 14 days
at 40, 32, or 24 mg. The most common adverse events were neutropenia and febrile neutropenia.
Eight percent (4/52) of patients achieved major cytogenetic response and 6% (3/52) had a
complete or a partial response. Thirteen percent (2/15) of patients with chronic phase CML
achieved complete hematologic response. None of the patients with advanced CML or Ph+
ALL achieved major hematologic response [121].
A comprehensive description of clinical trials performed with the different Aurora kinase
inhibitors has been recently reported [109, 110].
5. Aurora kinases and thyroid cancers
Normal human thyrocytes express all three Aurora kinases in a cell cycle-dependent manner
[98]. The expression of Aurora-A and Aurora-B in these cells is mainly regulated at the
transcriptional level, while that of Aurora-C appears to be modulated at the posttranscriptional
level [98]. An increased expression of all the Aurora kinases has been shown in various cell
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lines originating from different epithelial thyroid tumor histotypes, compared with normal
thyrocytes, as well as in DTC and ATC tissues, compared with normal matched tissues [60, 98,
122]. In addition, a study aimed to evaluate the gene expression profile in ATC identified
AURKA as one of the most frequently and most strongly overexpressed genes in these tumors
[123]. In fact, gain of chromosome 20q, where AURKA is located (20q13.2), is frequently
encountered in ATC [124]. Based on these findings, the potential therapeutic value of Aurora
kinase inhibition on the proliferation and growth of PTC and ATC cells has been evaluated in
preclinical studies [125–130]. In particular, different pan-Aurora kinase inhibitors, including
the MK-0457 (VX-680), the SNS-314 mesylate, and the ZM447439 have been evaluated in vitro
[126–129]. These molecules were found to inhibit proliferation of ATC cells in a time- and dose-
dependent manner and to impair cancer cell colony formation in soft agar. Cell cultures
exposed to pan-Aurora inhibitors revealed an accumulation of tetra- and polyploid cells
because of endoreplication events followed by the activation of caspase-3 and accumulation
of a sub-G0/G1 cell population, both indicative of apoptosis [126–129]. Treated cells showed
mitotic alterations consistent with the inhibition of Aurora kinases, including major impair-
ment of centrosome functions, with abnormal spindle formation characterized by the presence
of short microtubules, inhibition of histone H3 phosphorylation, and inability to complete the
cytokinesis. The effects of a selective inhibition of either Aurora-A or Aurora-B have been also
explored [125, 129, 131]. The selective inhibition of Aurora-B expression, by means of RNA
interference, or function, by means of small-molecule compounds (e.g., AZD1152), has been
reported to significantly reduce growth and tumorigenicity of ATC-derived cells, both in vivo
and in vitro [125]. In the same way, functional inhibition of Aurora-A by MLN8054 in a panel
of ATC-derived cell lines has been shown to block cell proliferation and to induce cell cycle
arrest and apoptosis [129]. In xenograft experiments, the drug was capable of reducing tumor
volume by 86% [129]. Interestingly, the combined treatment with MLN8054 and bortezomib,
targeting the ubiquitin-proteasome system, showed additive effects on ATC-derived cell
proliferation and apoptosis, compared with monotherapy [131]. More recently, pazopanib, a
multi-target inhibitor of tyrosine kinases including the VEGFR (vascular endothelial growth
factor receptor), shown to have impressive therapeutic activity in patients affected by radio-
active iodine-refractory DTC, was tested in a phase II clinical trial on ATC patients [132, 133].
Despite several of them treated with pazopanib had a transient disease regression, no response
evaluation criteria in solid tumors (RECIST) response was obtained [131]. Moreover, in a
preclinical study on a panel of ATC-derived cell lines, pazopanib was found to potentiate the
cytotoxic effects of paclitaxel in vitro and in xenograft experiments [134]. These pazopanib
effects were attributed to an unexpected off-target inhibition of Aurora-A in ATC-derived cell
lines. In fact, the same results were obtained when combining paclitaxel and MLN8237, a
selective Aurora-A inhibitor. In the same study, the authors also showed that the combined
administration of pazopanib and paclitaxel attained a marked and durable regression of lung
metastasis in a single ATC patient [134].
In conclusion, the preclinical and clinical data so far available indicate that Aurora kinase
inhibitors may have a therapeutic potential for the treatment of the more aggressive thyroid
cancers either in monotherapy or, more likely, in combination therapy with antimicrotubule
drugs.
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